Rule of thumb on VTE risks: Normal population 0-.4/100PYs; RA patients are increased at 0.3-0.7/100 PY. If a new RA drug were to cause VTE (venous thromboembolic events; DVT/PE) it would have to have a rate consistently higher than 0.5 and probably higher than 0.7/100PY